Duman, Belgin SüsleyiciÖztürk, MelekYilmazer, SelmaÇağatay, PenbeHatemi, Hüsrev2019-06-272019-06-27200670263-64841099-08440263-64841099-0844https://hdl.handle.net/20.500.12469/1231https://doi.org/10.1002/cbf.1218We have examined the frequency of the EcoRI XbaI and MspI RFLPs of the apolipoprotein B (apo 13) gene in I 10 type 2 diabetic patients and 9 1 healthy control subjects in order to ascertain whether variation in this gene may influence the development of non-insulin dependent diabetes mellitus (type 2 diabetes). Serum lipids including total-cholesterol (T-Chol) triacylglycerol (TAG) apolipoprotein E (apo E) apolipoprotein Al (apo Al) apolipoprotein B and lipoprotein (a) (Lp(a)) were analysed. Genomic DNA was extracted and the apo B polymorphic regions amplified by the polymerase chain reaction. Regions carrying EcoRI XbaI and MspI restriction sites present in the apo B gene were amplified and digested separately by the respective enzymes. No significant difference for genotypic frequencies was observed for the EcoRI XbaI and MspI restriction sites in type 2 diabetic patients as compared to controls. Type 2 diabetic patients and controls with EcoRI +/+ and XbaI +/+ genotypes had higher apo E levels. The MspI +/+ genotype is more frequent in the patient and control groups With elevated T-Chol. Furthermore the EcoRI -/- XbaI -/- and MspI +/+ genotypes were found to be significantly more frequent in type 2 diabetic patients with higher blood glucose levels. This study identifies the apo B gene polymorphisms in modulating plasma lipid/lipoprotein and glucose levels in patients with type 2 diabetes. Copyright 0 2005 John Wiley & Sons Ltd.eninfo:eu-repo/semantics/openAccessNon-insulin dependent diabetes mellitusApolipoprotein BPolymorphismArticle261267324WOS:00023787260001010.1027/cbf.12182-s2.0-33646790855Q3Q216634094